SG Americas Securities LLC lifted its stake in shares of Blueprint Medicines Corporation (NASDAQ:BPMC) by 110.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 8,673 shares of the biotechnology company’s stock after acquiring an additional 4,560 shares during the period. SG Americas Securities LLC’s holdings in Blueprint Medicines were worth $604,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Cambridge Investment Research Advisors Inc. bought a new stake in Blueprint Medicines in the third quarter worth $244,000. Bank of New York Mellon Corp lifted its stake in Blueprint Medicines by 0.8% in the third quarter. Bank of New York Mellon Corp now owns 176,029 shares of the biotechnology company’s stock worth $12,264,000 after purchasing an additional 1,326 shares during the last quarter. Rhumbline Advisers lifted its stake in Blueprint Medicines by 3.0% in the third quarter. Rhumbline Advisers now owns 45,033 shares of the biotechnology company’s stock worth $3,137,000 after purchasing an additional 1,329 shares during the last quarter. New York State Common Retirement Fund lifted its stake in Blueprint Medicines by 8.6% in the third quarter. New York State Common Retirement Fund now owns 48,507 shares of the biotechnology company’s stock worth $3,379,000 after purchasing an additional 3,835 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Blueprint Medicines by 64.1% in the third quarter. Sei Investments Co. now owns 59,251 shares of the biotechnology company’s stock worth $4,128,000 after purchasing an additional 23,151 shares during the last quarter. 91.40% of the stock is owned by institutional investors and hedge funds.

In related news, insider Anthony L. Boral sold 5,000 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $70.40, for a total transaction of $352,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kate Haviland sold 6,356 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $60.03, for a total transaction of $381,550.68. Following the transaction, the insider now owns 6,356 shares in the company, valued at approximately $381,550.68. The disclosure for this sale can be found here. Insiders have sold 72,639 shares of company stock worth $4,871,743 in the last quarter. 3.40% of the stock is owned by corporate insiders.

Blueprint Medicines Corporation (BPMC) opened at $71.86 on Friday. Blueprint Medicines Corporation has a 52-week low of $25.34 and a 52-week high of $77.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.06). Blueprint Medicines had a negative net margin of 437.83% and a negative return on equity of 43.11%. The firm had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $5.35 million. During the same quarter in the previous year, the firm posted ($0.62) EPS. Blueprint Medicines’s revenue was up 31.0% compared to the same quarter last year. research analysts forecast that Blueprint Medicines Corporation will post -3.76 EPS for the current year.

Several research firms have weighed in on BPMC. Wedbush reissued an “outperform” rating and issued a $82.00 price target (up from $70.00) on shares of Blueprint Medicines in a research note on Monday, November 6th. ValuEngine cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research report on Tuesday, October 31st. DA Davidson assumed coverage on shares of Blueprint Medicines in a research report on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective on the stock. Finally, BTIG Research assumed coverage on shares of Blueprint Medicines in a research report on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $75.13.

TRADEMARK VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/12/09/blueprint-medicines-corporation-bpmc-shares-bought-by-sg-americas-securities-llc.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Stock Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related stocks with our FREE daily email newsletter.